Skip to content

Trial of Yoga in patients with Multiple Sclerosis

Randomised trial of Yoga as an add on therapy in patients with Multiple Sclerosis. RESET-MS. - RESET-MS.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/07/020263
Enrollment
200
Registered
2019-07-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G053- Encephalitis and encephalomyelitisin diseases classified elsewhere

Interventions

Intervention1: Yoga: The intervention group will be taught yoga practices as per a defined protocol by trained yoga therapist at the centre for integrative medicine and research (CIMR), AIIMS, New Del

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. A diagnosis of CDMS (clinically defined multiple sclerosis) (using revised McDonald criteria, 2010, 2017 revision) 2. RRMS, SPMS, PPMS. 3. Within 5 years from onset 4. Written informed consent 5. Males or females, aged between 18 to 50 6. Indian origin 7. EDSS (Expanded Disability Status Scale) score between 0 and 6

Exclusion criteria

Exclusion criteria: 1. Any condition which in the opinion of the investigator would render the patient unsuitable. 2. Any concurrent illness, disability, or clinically significant abnormality (including laboratory tests) that may prevent the subject from safely completing the assessments required by the protocol.

Design outcomes

Primary

MeasureTime frame
1. To assess if yoga added to the medical management improves fatigue among patients with MS 2. To assess if yoga added to the standard medical management improves walking ability on 8 metres / 25 feet walk test and overall improvement in ambulation using EDSS scale.Timepoint: 3, 6, 12 months

Secondary

MeasureTime frame
To assess if yoga added to the medical management improves spasticity, quality of life, depression, bladder functions and disease related outcomes as measured on relapse rate, disability progression and MRI measures AND prevents disability progression as measured on the EDSS scale among patients with MS .Timepoint: 3, 6, 12 months

Countries

India

Contacts

Public ContactRohit Bhatia

AIIMS. New Delhi

rohitbhatia71@yahoo.com01126546625

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026